Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generator
ABBOTT MEDICAL · Decision date Oct 27, 2026
What did the FDA decide?
The FDA record for P010032/S265 describes a 30-Day Notice submitted by Abbott Medical covering a change in how the feedthrough component is manufactured for the implantable pulse generators used in its spinal cord stimulator and deep brain stimulator systems. The supplement reason is listed as a process change involving a manufacturer, sterilizer, packager or supplier. The affected device category is a totally implanted spinal cord stimulator for pain relief, under product code LGW in neurology. The decision, dated 2026-10-27, is recorded as OK30.
The identifier ties this filing to the original PMA P010032 as a supplement, so it is a manufacturing change notice rather than approval of a new system. The statement gives the component and the systems involved but not the specific manufacturing step altered, the validation data reviewed, or any clinical or safety conclusions. Those details are absent, and the OK30 entry is not independent proof of safety or effectiveness.
FDA approval order statement
approval for a change in the manufacturing of the feedthrough component utilized in the Implantable Pulse Generators (IPGs) of the Spinal Cord Stimulator and Deep Brain Stimulator systems
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010032/S265
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LGW
- Decision code
- OK30
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Abbott Medical
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010032 · Original PMA
GENESIS AND EON FAMILY NEUROSTIMULATION (IPG) SYSTEMS
P010032/S261 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S251 · Related supplement
Quattrode; Octrode; Penta; Lamitrode; Tripole; TriCentrus Lead Extensions
P010032/S260 · Related supplement
Proclaim family of SCS IPG
P010032/S265 received
Application receipt date recorded by FDA.
P010032/S265 · FDA decision
30-Day Notice
P010032/S262 · Related supplement
Spinal Cord Stimulation (SCS) External Pulse Generator (EPG)
P010032/S264 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S266 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG)
Timeline entries are records held by MedtechLedger for P010032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Nov 21, 2001 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 18, 2026 | FDA | |
Proclaim family of SCS IPGP010032/S260 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Preston Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P010032/S265
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





